Skip to main content

Elevated magnetic resonance imaging measures of adipose tissue deposition in women with breast cancer treatment-related lymphedema

Abstract

Purpose

Breast cancer treatment-related lymphedema (BCRL) is a common co-morbidity of breast cancer therapies, yet factors that contribute to BCRL progression remain incompletely characterized. We investigated whether magnetic resonance imaging (MRI) measures of subcutaneous adipose tissue were uniquely elevated in women with BCRL.

Methods

MRI at 3.0 T of upper extremity and torso anatomy, fat and muscle tissue composition, and T2 relaxometry were applied in left and right axillae of healthy control (n = 24) and symptomatic BCRL (n = 22) participants to test the primary hypothesis that fat-to-muscle volume fraction is elevated in symptomatic BCRL relative to healthy participants, and the secondary hypothesis that fat-to-muscle volume fraction is correlated with MR relaxometry of affected tissues and BCRL stage (significance criterion: two-sided p < 0.05).

Results

Fat-to-muscle volume fraction in healthy participants was symmetric in the right and left sides (p = 0.51); in BCRL participants matched for age, sex, and BMI, fat-to-muscle volume fraction was elevated on the affected side (fraction = 0.732 ± 0.184) versus right and left side in controls (fraction = 0.545 ± 0.221, p < 0.001). Fat-to-muscle volume fraction directly correlated with muscle T2 (p = 0.046) and increased with increasing level of BCRL stage (p = 0.041).

Conclusion

Adiposity quantified by MRI is elevated in the affected upper extremity of women with BCRL and may provide a surrogate marker of condition onset or severity.

Clinical trial

NCT02611557.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Data availability

The datasets generated during the current study are available from the corresponding author on reasonable request.

Code availability

Code generated during the current study is available from the corresponding author on reasonable request.

References

  1. 1.

    U.S. Breast Cancer Statistics (2021) Retrieved from https://www.breastcancer.org/symptoms/understand_bc/statistics

  2. 2.

    DiSipio T, Rye S, Newman B, Hayes S (2013) Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol 14(6):500–515

    Article  Google Scholar 

  3. 3.

    Boyages J, Xu Y, Kalfa S, Koelmeyer L, Parkinson B, Mackie H, Viveros H, Gollan P, Taksa L (2017) Financial cost of lymphedema borne by women with breast cancer. Psychooncology 26(6):849–855

    Article  Google Scholar 

  4. 4.

    Rockson SG, Rivera KK (2008) Estimating the population burden of lymphedema. Ann N Y Acad Sci 1131:147–154

    Article  Google Scholar 

  5. 5.

    Rockson SG, Keeley V, Kilbreath S, Szuba A, Towers A (2019) Cancer-associated secondary lymphoedema. Nat Rev Dis Primers 5(1):22

    Article  Google Scholar 

  6. 6.

    Chen CM, Cano SJ, Klassen AF, King T, McCarthy C, Cordeiro PG, Morrow M, Pusic AL (2010) Measuring quality of life in oncologic breast surgery: a systematic review of patient-reported outcome measures. Breast J 16(6):587–597

    Article  Google Scholar 

  7. 7.

    Penha TR, Botter B, Heuts EM, Voogd AC, von Meyenfeldt MF, van der Hulst RR (2016) Quality of life in patients with breast cancer-related lymphedema and reconstructive breast surgery. J Reconstr Microsurg 32(6):484–490

    Article  Google Scholar 

  8. 8.

    Shah C, Arthur DW, Wazer D, Khan A, Ridner S, Vicini F (2016) The impact of early detection and intervention of breast cancer-related lymphedema: a systematic review. Cancer Med 5(6):1154–1162

    Article  Google Scholar 

  9. 9.

    McDuff SGR, Mina AI, Brunelle CL, Salama L, Warren LEG, Abouegylah M, Swaroop M, Skolny MN, Asdourian M, Gillespie T et al (2019) Timing of lymphedema after treatment for breast cancer: when are patients most at risk? Int J Radiat Oncol Biol Phys 103(1):62–70

    Article  Google Scholar 

  10. 10.

    Michelotti A, Invernizzi M, Lopez G, Lorenzini D, Nesa F, De Sire A, Fusco N (2019) Tackling the diversity of breast cancer related lymphedema: perspectives on diagnosis, risk assessment, and clinical management. Breast 44:15–23

    Article  Google Scholar 

  11. 11.

    Sayegh HE, Asdourian MS, Swaroop MN, Brunelle CL, Skolny MN, Salama L, Taghian AG (2017) Diagnostic methods, risk factors, prevention, and management of breast cancer-related lymphedema: past, present, and future directions. Curr Breast Cancer Rep 9(2):111–121

    CAS  Article  Google Scholar 

  12. 12.

    Rockson SG (2010) Current concepts and future directions in the diagnosis and management of lymphatic vascular disease. Vasc Med 15(3):223–231

    Article  Google Scholar 

  13. 13.

    Crescenzi R, Donahue PMC, Hartley KG, Desai AA, Scott AO, Braxton V, Mahany H, Lants SK, Donahue MJ (2017) Lymphedema evaluation using noninvasive 3T MR lymphangiography. J Magn Reson Imaging 46(5):1349–1360

    Article  Google Scholar 

  14. 14.

    Borri M, Schmidt MA, Gordon KD, Wallace TA, Hughes JC, Scurr ED, Koh DM, Leach MO, Mortimer PS (2015) Quantitative contrast-enhanced magnetic resonance lymphangiography of the upper limbs in breast cancer related lymphedema: an exploratory study. Lymphat Res Biol 13(2):100–106

    Article  Google Scholar 

  15. 15.

    Lu Q, Xu J, Liu N (2010) Chronic lower extremity lymphedema: a comparative study of high-resolution interstitial MR lymphangiography and heavily T2-weighted MRI. Eur J Radiol 73(2):365–373

    Article  Google Scholar 

  16. 16.

    Cellina M, Martinenghi C, Panzeri M, Soresina M, Menozzi A, Daniele G, Oliva G (2021) Noncontrast MR lymphography in secondary lower limb lymphedema. J Magn Reson Imaging 53(2):458–466

    Article  Google Scholar 

  17. 17.

    Donahue PMC, Crescenzi R, Lee C, Garza M, Patel NJ, Petersen KJ, Donahue MJ (2020) Magnetic resonance imaging and bioimpedance evaluation of lymphatic abnormalities in patients with breast cancer treatment-related lymphedema. Breast Cancer Res Treat 183(1):83–94

    Article  Google Scholar 

  18. 18.

    Donahue PM, Crescenzi R, Scott AO, Braxton V, Desai A, Smith SA, Jordi J, Meszoely IM, Grau AM, Kauffmann RM et al (2017) Bilateral changes in deep tissue environment after manual lymphatic drainage in patients with breast cancer treatment-related lymphedema. Lymphat Res Biol 15(1):45–56

    Article  Google Scholar 

  19. 19.

    Crescenzi R, Donahue PMC, Mahany H, Lants SK, Donahue MJ (2020) CEST MRI quantification procedures for breast cancer treatment-related lymphedema therapy evaluation. Magn Reson Med 83(5):1760–1773

    CAS  Article  Google Scholar 

  20. 20.

    Donahue MJ, Donahue PC, Rane S, Thompson CR, Strother MK, Scott AO, Smith SA (2016) Assessment of lymphatic impairment and interstitial protein accumulation in patients with breast cancer treatment-related lymphedema using CEST MRI. Magn Reson Med 75(1):345–355

    CAS  Article  Google Scholar 

  21. 21.

    Swartz MA (2001) The physiology of the lymphatic system. Adv Drug Deliv Rev 50(1–2):3–20

    CAS  Article  Google Scholar 

  22. 22.

    Huang LH, Elvington A, Randolph GJ (2015) The role of the lymphatic system in cholesterol transport. Front Pharmacol 6:182

    PubMed  PubMed Central  Google Scholar 

  23. 23.

    Wong BW, Wang X, Zecchin A, Thienpont B, Cornelissen I, Kalucka J, Garcia-Caballero M, Missiaen R, Huang H, Bruning U et al (2017) The role of fatty acid beta-oxidation in lymphangiogenesis. Nature 542(7639):49–54

    CAS  Article  Google Scholar 

  24. 24.

    Rutkowski JM, Moya M, Johannes J, Goldman J, Swartz MA (2006) Secondary lymphedema in the mouse tail: lymphatic hyperplasia, VEGF-C upregulation, and the protective role of MMP-9. Microvasc Res 72(3):161–171

    CAS  Article  Google Scholar 

  25. 25.

    Rutkowski JM, Markhus CE, Gyenge CC, Alitalo K, Wiig H, Swartz MA (2010) Dermal collagen and lipid deposition correlate with tissue swelling and hydraulic conductivity in murine primary lymphedema. Am J Pathol 176(3):1122–1129

    CAS  Article  Google Scholar 

  26. 26.

    Tashiro K, Feng J, Wu SH, Mashiko T, Kanayama K, Narushima M, Uda H, Miyamoto S, Koshima I, Yoshimura K (2017) Pathological changes of adipose tissue in secondary lymphoedema. Br J Dermatol 177(1):158–167

    CAS  Article  Google Scholar 

  27. 27.

    Li CY, Kataru RP, Mehrara BJ (2020) Histopathologic features of lymphedema: a molecular review. Int J Mol Sci 21(7):2546

    CAS  Article  Google Scholar 

  28. 28.

    Rane S, Donahue PM, Towse T, Ridner S, Chappell M, Jordi J, Gore J, Donahue MJ (2013) Clinical feasibility of noninvasive visualization of lymphatic flow with principles of spin labeling MR imaging: implications for lymphedema assessment. Radiology 269(3):893–902

    Article  Google Scholar 

  29. 29.

    Brorson H, Ohlin K, Olsson G, Karlsson MK (2009) Breast cancer-related chronic arm lymphedema is associated with excess adipose and muscle tissue. Lymphat Res Biol 7(1):3–10

    Article  Google Scholar 

  30. 30.

    Idy-Peretti I, Bittoun J, Alliot FA, Richard SB, Querleux BG, Cluzan RV (1998) Lymphedematous skin and subcutis: in vivo high resolution magnetic resonance imaging evaluation. J Invest Dermatol 110(5):782–787

    CAS  Article  Google Scholar 

  31. 31.

    Borri M, Gordon KD, Hughes JC, Scurr ED, Koh DM, Leach MO, Mortimer PS, Schmidt MA (2017) Magnetic resonance imaging-based assessment of breast cancer-related lymphoedema tissue composition. Invest Radiol 52(9):554–561

    Article  Google Scholar 

  32. 32.

    Sen Y, Qian Y, Koelmeyer L, Borotkanics R, Ricketts R, Mackie H, Lam TC, Ho Shon K, Suami H, Boyages J (2017) Breast cancer-related lymphedema: differentiating fat from fluid using magnetic resonance imaging segmentation. Lymphat Res Biol. https://doi.org/10.1089/lrb.2016.0047

    Article  PubMed  Google Scholar 

  33. 33.

    Crescenzi R, Donahue PM, Braxton VG, Scott AO, Mahany HB, Lants SK, Donahue MJ (2018) 3.0 T relaxation time measurements of human lymph nodes in adults with and without lymphatic insufficiency: implications for magnetic resonance lymphatic imaging. NMR Biomed 31(12):e4009

    Article  Google Scholar 

  34. 34.

    Gold GE, Han E, Stainsby J, Wright G, Brittain J, Beaulieu C (2004) Musculoskeletal MRI at 3.0 T: relaxation times and image contrast. Am J Roentgenol 183(2):343–351

    Article  Google Scholar 

  35. 35.

    Kataru RP, Park HJ, Baik JE, Li C, Shin J, Mehrara BJ (2020) Regulation of lymphatic function in obesity. Front Physiol 11:459

    Article  Google Scholar 

  36. 36.

    Wang Y, Oliver G (2010) Current views on the function of the lymphatic vasculature in health and disease. Genes Dev 24(19):2115–2126

    CAS  Article  Google Scholar 

  37. 37.

    Fu MR, Axelrod D, Guth AA, Fletcher J, Qiu JM, Scagliola J, Kleinman R, Ryan CE, Chan N, Haber J (2015) Patterns of obesity and lymph fluid level during the first year of breast cancer treatment: a prospective study. J Pers Med 5(3):326–340

    Article  Google Scholar 

  38. 38.

    Ching DL, Anderson A, Kumarasinghe SP (2015) Lower limb lymphoedema and obesity: a much-neglected association. Br J Hosp Med (Lond) 76(9):542–543

    Article  Google Scholar 

  39. 39.

    Yamamoto T, Yamamoto N, Yamashita M, Furuya M, Hayashi A, Koshima I (2016) Efferent lymphatic vessel anastomosis: supermicrosurgical efferent lymphatic vessel-to-venous anastomosis for the prophylactic treatment of subclinical lymphedema. Ann Plast Surg 76(4):424–427

    CAS  Article  Google Scholar 

  40. 40.

    Yamamoto T, Yoshimatsu H, Yamamoto N (2016) Complete lymph flow reconstruction: a free vascularized lymph node true perforator flap transfer with efferent lymphaticolymphatic anastomosis. J Plast Reconstr Aesthet Surg 69(9):1227–1233

    Article  Google Scholar 

  41. 41.

    Hadamitzky C, Zaitseva TS, Bazalova-Carter M, Paukshto MV, Hou L, Strassberg Z, Ferguson J, Matsuura Y, Dash R, Yang PC et al (2016) Aligned nanofibrillar collagen scaffolds—guiding lymphangiogenesis for treatment of acquired lymphedema. Biomaterials 102:259–267

    CAS  Article  Google Scholar 

  42. 42.

    Tian W, Rockson SG, Jiang X, Kim J, Begaye A, Shuffle EM, Tu AB, Cribb M, Nepiyushchikh Z, Feroze AH et al (2017) Leukotriene B4 antagonism ameliorates experimental lymphedema. Sci Transl Med. https://doi.org/10.1126/scitranslmed.aal3920

    Article  PubMed  Google Scholar 

  43. 43.

    Chang DW, Dayan J, Greene AK, MacDonald JK, Masia J, Mehrara B, Neligan PC, Nguyen D (2021) Surgical treatment of lymphedema: a systematic review and meta-analysis of controlled trials. Results of a consensus conference. Plast Reconstr Surg 147(4):975–993

    CAS  Article  Google Scholar 

Download references

Acknowledgements

We are grateful to Christopher Thompson, Clair Jones, Marisa Bush, Joshua Hageman, Charles Nockowski, and Ryan Robinson for experimental support.

Funding

This research was funded by Grant Nos. NIH/NINR 1R01NR015079, NIH/NHLBI 1R01HL155523, the Lipedema Foundation (LF) Postdoctoral Research Fellowship, LF Collaborative Grant #12, American Heart Association (AHA) 18CDA34110297, and AHA 19IPLOI34760518. Imaging experiments were performed in the Vanderbilt Human Imaging Core using research resources supported by the NIH grant 1S10OD021771-01. Recruitment through www.ResearchMatch.org and services at the Clinical Research Center are supported by the National Center for Advancing Translational Sciences (NCATS) Clinical Translational Science Award (CTSA) Program, award number 5UL1TR002243-03. REDCap resources were provided by NCATS/NIH UL1 TR000445. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Author information

Affiliations

Authors

Contributions

All authors contributed to the study conception and design. Material preparation and data collection were performed by RC, PD, MD, MG, CL, and NP. Analyses were performed by RC, MD, PD, SJ, and VG. The first draft of the manuscript was written by RC and MD. All authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Rachelle Crescenzi.

Ethics declarations

Conflict of interest

PMCD is a paid consultant for PureTech Health and Tactile Medical and has received clinical and imaging grants from LymphaTouch Inc. MJD receives research-related support from Philips North America; is a paid consultant for Pfizer Inc, Global Blood Therapeutics, and LymphaTouch; is a paid advisory board member for Novartis and bluebird bio; receives research funding from Pfizer Inc; and is the CEO of Biosight, LLC which provides healthcare technology consulting services. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

Ethical approval

This study was approved by the Vanderbilt University Medical Center Institutional Review Board.

Consent to participate

All participants provided written informed consent before study participation.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 30 KB)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Crescenzi, R., Donahue, P.M.C., Garza, M. et al. Elevated magnetic resonance imaging measures of adipose tissue deposition in women with breast cancer treatment-related lymphedema. Breast Cancer Res Treat (2021). https://doi.org/10.1007/s10549-021-06419-w

Download citation

Keywords

  • Breast cancer
  • Lymphedema
  • MRI
  • MR relaxometry
  • Adipose tissue
  • Edema